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Abstract
Background: In our previous study, monogalactosyl diacylglycerol (MGDG) purified from spinach was found to
have cytotoxic effects in human cancer cell lines. This study further assessed whether MGDG can enhance the
cytotoxic effects of radiation in human pancreatic cancer cells in vitro and in vivo.
Methods: Glycoglycerolipids from spinach including MGDG were extracted from dried spinach. The cytotoxicity of
MGDG were evaluated by the MTT assay using four human pancreatic cancer cell lines (MIAPaCa-2, AsPC-1, BxPC-3
and PANC-1) and normal human dermal fibroblasts (NHDFs). The effects of radiation and MGDG alone or in
combination in MIAPaCa-2 cells was analyzed with the colony forming and apoptosis assays, western blotting and
cell cycle and DNA damage analyses (γ-H2AX foci staining and comet assay). The inhibitory effects on tumor
growth were assessed in a mouse xenograft tumor model.
Results: MGDG showed dose- and time-dependent cytotoxicity, with half-maximal inhibitory concentrations (IC50)
in PANC-1, BxPC-3, MIAPaCa-2 and AsPC-1 cells at 72 h of 25.6 ± 2.5, 26.9 ± 1.3, 18.5 ± 1.7, and 22.7 ± 1.9 μM,
respectively. The colony forming assay revealed fewer MIAPaCa-2, BxPC-3 and AsPC-1 cell colonies upon treatment
with both MGDG and radiation as compared to irradiation alone (P < 0.05). The combination of MGDG and
radiation induced a higher proportion of apoptosis in MIAPaCa-2 cells; this effect was associated with increased
mitochondrial release of cytochrome c and activation of cleaved poly (ADP-ribose) polymerase and caspase-3. DNA
damage was detected and DNA repair mechanisms were more frequently impaired in cells receiving the
combination treatment as compared to either one alone. Tumor growth was inhibited to a greater degree in mice
treated by intratumoral injection of MGDG combined with irradiation as compared to either one alone (P < 0.05).
Conclusions: This is the first report demonstrating that MGDG enhances the cytotoxicity of radiation to induce
apoptosis of cancer cells in vitro and in vivo. Our findings indicate that this therapeutic combination can be an
effective strategy for the treatment of pancreatic cancer.
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Background
Pancreatic cancer remains a major public health issue as
the third leading cause of cancer-related death in
Europe, the fourth in the United States, and the fifth
(men) or sixth (women) in Japan [1–3]. Recent in vitro
and in vivo studies have shown that consumption of veg-
etables and fruits with chemopreventive components
can reduce cancer risk [4–6]. The chloroplast thylakoid
membrane of higher plants contains glycoglycerolipids
such as monogalactosyl diacylglycerol (MGDG), digalac-
tosyl diacylglycerol (DGDG) and sulfoquinovosyl diacyl-
glycerol (SQDG) [7]; these compounds have potential
anti-cancer functions including inhibition of DNA poly-
merase and suppression of cancer cell proliferation [8],
with MGDG showing more potent anti-tumorigenic and
anti-inflammatory activity than the others [9]. Spinach is
a major source of glycoglycerolipids and has the highest
MGDG content among vegetables, fruits and grains
tested to date [10–12].
Various approaches have been used to improve the
survival rate of pancreatic cancer patients, including ad-
juvant chemotherapy [13–15], preoperative chemoradio-
therapy [16–18], and induction chemotherapy followed
by chemoradiotherapy [19, 20]. Our previous study
showed that MGDG enhanced the cytotoxic effects of
gemcitabine (GEM)—a key drug for treating pancreatic
cancer—possibly by selectively inhibiting mammalian
replicative DNA polymerases, specifically pol γ [21].
The present study further investigated whether
MGDG might enhance the effects of radiation on human
pancreatic cancer cell lines in vitro and in vivo.
Methods
Isolation of MGDG from spinach
The spinach (Spinacia oleracea) subspecies Anna was
used in this study. Dried spinach was extracted with
ethanol; the extract was diluted in 70% aqueous ethanol
and subjected to Diaion HP-20 column chromatography
(Sigma-Aldrich, St. Louis, MO, USA), then eluted with
95% aqueous ethanol. The eluate was evaporated to
dryness; the residue was redissolved in chloroform and
the resultant solution was subjected to PSQ60B silica gel
column chromatography (Fuji Silysia Chemical, Tokyo,
Japan). After washing with chloroform/ethyl acetate
(1:1 v/v), the column was eluted with ethyl acetate and
the eluate was purified using a Sep-Pak C18 cartridge
(Waters, Milford, MA, USA) that was then eluted with
methanol. The MGDG fraction was evaporated, yielding
pure MGDG (~98%). The purity was confirmed by
normal-phase silica gel high-performance liquid chroma-
tography (Shiseido, Tokyo, Japan) coupled to an evap-
orative light scattering detector (M&S Instruments,
Osaka, Japan), with chloroform/methanol (1/1, v/v) used
as the eluent.
Cell culture and viability assessment
MIAPaCa-2, PANC-1, BxPC-3 and AsPC-1 human pan-
creatic cancer cell lines as well as Raji and HL60 cells
were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA) and cultured in Roswell Park
Memorial Institute 1640 medium supplemented with
10% fetal bovine serum, penicillin (100 U/ml), strepto-
mycin (100 μg/ml). HCT116 colon carcinoma cell lines
with wild-type p53 (HCT116 p53+/+) and their isogenic
derivatives lacking p53 (HCT116 p53−/−) were a gift
from Dr. Bert Vogelstein (Johns Hopkins University,
Baltimore, MD, USA). The cells were maintained in
McCoy’s 5A medium. Primary normal human dermal fi-
broblasts (NHDFs) were purchased from Cell Systems
Corp. (Kirkland, WA, USA) and maintained according
to the supplier’s instructions. The cytotoxicity of MGDG
was evaluated with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay. The cytotox-
icity when combined with irradiation was assessed with
the colony forming assay. For the MTT assay, cells were
treated with 0, 2, 5, 10, 20, 50 or 100 μM MGDG or cor-
responding doses of dimethyl sulfoxide (DMSO) for 24,
48 or 72 h at 37 °C in a humidified atmosphere of 5%
CO2; 2 h after adding MTT solution (0.6 mg/ml in Milli-
Q-purified water), cells were lysed in 200 μl of fresh
DMSO. For the colony forming assay, MIAPaCa-2,
BxPC-3 and AsPC-1 cells were treated with 40–60 μM
MGDG or 0.8% DMSO for 24 h, and then exposed to 0,
2, 4 and 8 Gy of radiation. After 9–12 days, colonies
were fixed with a solution of 10% methanol and 20%
acetic acid, stained with Methylene Blue and counted
under a light microscope.
X-ray irradiation
X-ray irradiation was performed using a MBR-1505R2
instrument (Hitachi, Tokyo, Japan) at a voltage of
150 kV and a current of 5 mA with a 1-mm-thick
aluminum filter (0.5 Gy/min at the target) for in vitro
and in vivo studies. Mice were anesthetized by intraperi-
toneal administration of somnopentyl (0.1 mg/g body
weight) and were then anesthetized and immobilized in
a customized harness that exposed the implanted tumors
while shielding the remainder of the body with lead
during irradiation.
Analysis of apoptotic cells
Apoptosis was evaluated based on DNA fragmentation
using the APO-Direct Assay Staining kit (BD Biosci-
ences, San Diego, CA, USA) as previously described
[22]. In this assay, DNA breaks are labeled with fluores-
cein isothiocyanate (FITC)-2′-deoxyuridine-5′-triphos-
phate and cells are analyzed by flow cytometry.
MIAPaCa-2 cells were treated with MGDG (25 μM)
alone for 24 h, radiation (5 Gy) alone for 12 h, or with a
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combination of both. The cells were harvested by trypsi-
nization, washed with phosphate-buffered saline (PBS),
and then fixed in 1% paraformaldehyde for 15min
followed by 70% ethanol overnight at −20 °C. A DNA la-
beling solution containing FITC was added for 30min;
the cells were the resuspended in PBS, and apoptosis
was detected by flow cytometry on a FACS Calibur in-
strument (Becton Dickinson, Franklin Lakes, NJ, USA).
Data were analyzed with CellQuest software (Becton
Dickinson), and apoptotic cells were quantified as a
percentage of the total number of cells.
Western blot analysis
MIAPaCa-2 cells were seeded at a density of 2 × 106/
well in a 6-well plate for 24 h, then washed with PBS
and incubated with various concentrations of MGDG
for 24 h. Cells were washed twice with PBS and lysed in
lysis buffer composed of 20 mM HEPES (pH 7.5), 10%
glycerol, 1.5 mM MgCl2, 1 mM TritonX-100, and pro-
tease inhibitor cocktail (Roche Life Science, Tokyo,
Japan) followed by boiling for 5min. To isolate cytosolic
and mitochondrial fractions, MIAPaCa-2 cells were
harvested by scraping on ice, and resuspended in 500 μl
buffer A composed of 20 mM HEPES (pH 7.5), 10 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, and
protease inhibitor cocktail. After incubation on ice for
1 h, cells were lysed by repeated passage (20–30 times)
through a 27-gauge needle. The lysates were centri-
fuged at 750 × g for 5min at 4 °C and the supernatant
was centrifuged at 10,000 × g for 15min at 4 °C. The
mitochondrial pellet was washed once in buffer A and
lysed in Laemmli sample buffer. The supernatant was
centrifuged at 100,000 × g for 30min at 4 °C to obtain
the cytosolic fraction. Protein concentrations were
measured with the bicinchoninic acid protein assay kit
(Pierce Biotechnology, Rockford, IL, USA) according to
the manufacturer’s protocol. Proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and then transferred to nitrocellulose membranes
that were blocked with 5% non-fat milk in PBS and
probed overnight at 4 °C with primary antibodies
against the following proteins: actin (Santa Cruz Bio-
technology, Dallas, TX, USA), poly (ADP-ribose) poly-
merase (PARP) (Cell Signaling Technology, Danvers,
MA, USA), caspase-3 (Cell Signaling Technology),
pro-caspase-3 (GeneTex, Irvine, CA, USA), B cell
lymphoma (Bcl)-2 (Santa Cruz Biotechnology), and
Bcl-2-associated X protein (Bax) (Santa Cruz Biotech-
nology). Immunoreactivity was detected with an en-
hanced chemiluminescence kit (GE Healthcare, Little
Chalfont, UK) and protein bands were visualized
using an Amersham Imager 600 (GE Healthcare). Signal
intensity was quantified using Multi Gauge v.3.0 software
(Fujifilm, Tokyo, Japan).
Cell cycle analysis
The effect of MGDG on the cell cycle was evaluated by
flow cytometry as previously described [23]. Briefly,
MIAPaCa-2 cells (3 × 105 cells in a 25-ml flask) were
treated with 40 μM MGDG, 8 Gy of radiation, or a com-
bination of both for 24 h. Cells were irradiated within
12 h of adding MGDG and incubated for 12 h, then
fixed on ice for 30min in PBS (pH 7.4) containing 2%
formaldehyde and stored at −20 °C until analysis. Cells
were washed and incubated for 15min in phosphate cit-
ric acid buffer composed of 20% Triton X and 5 mg/ml
ribonuclease A in PBS, then resuspended in 50 mg/ml
propidium iodide for at least 15min at room
temperature in the dark; the DNA content of the sam-
ples was analyzed by flow cytometry using a FACScan
instrument (Becton Dickinson) with a 488-nm laser run
at 15 mW and a 585/420-nm bandpass filter. At least
20,000 events were acquired using CellQuest software
(Becton Dickinson). The experiment was performed at
least twice. The G1, S and G2 fractions were identified
by selecting the areas consisting of living cells and
excluding those containing dead cells.
Detection of DNA damage in vitro
Induction of DNA damage was investigated by detecting
phosphorylated histone 2AX (γ-H2AX)-positive foci by
immunocytochemistry [24]. Briefly, MIAPaCa-2 cells
were subcultured in 35-mm dishes and treated with
40 μM MGDG for 1 h and/or 8 Gy of radiation. Cells
were then fixed in 4% paraformaldehyde in PBS for
20min, permeabilized with 0.1% Triton X-100 in PBS for
5min, and blocked in 5% bovine serum albumin in PBS
for 60min. The cells were incubated with rabbit anti γ-
H2AX antibody (1:200; Cell Signaling Technology,
Danvers, MA, US) overnight at 4 °C, followed by incuba-
tion with tetramethyl rhodamine isothiocyanate-conjugated
anti-rabbit secondary antibody (1:20; Dako, Glostrup,
Denmark) for 90min at room temperature. Nuclei were
Table 1 Cytotoxic effects of glycoglycerolipids from the spinach
on human cancer cell growth
IC50 (μM)
Cell type Tissue origin DGDG SQDG MGDG
HCT116 p53+/+ Colon 22 78 13
HCT116 p53−/− Colon 30 180 16
HL60 Leukemia 27 144 5
Raji Lymphoma 22 114 5
PANC-1 Pancreas 103 48 11
MIAPaCa-2 Pancreas 16 66 4
Median 26 96 8
DGDG digalactosyl diacylglycerol, IC50 half-maximal (50%) inhibitory concentra-
tion, MGDG monogalactosyl diacylglycerol, SQDG
sulfoquinovosyl diacylglycerol
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stained with 4′,6-diaidino-2- phenylindole, and cells were
visualized with a fluorescence microscope (BZ-9000;
Keyence, Osaka, Japan). Nuclear γ-H2AX foci in 200 cells
in each treatment group were manually counted, and data
are presented as the mean ± standard deviation of three
random fields.
Comet assay for detection of DNA repair impairment
The alkaline comet assay was performed using a kit
(Trevigen, Gaithersburg, MD, USA) according to the
manufacturer’s instructions. Briefly, 250 ml of 0.65%
normal agarose was prepared and a drop was placed on
a frosted slide, covered with a coverslip and allowed to
solidify. The cell suspension (100 ml) was mixed at 1:10
with 0.5% low-melting-point agarose and a 100 μl vol-
ume of the mixture was pipetted onto the slides and
allowed to solidify. A final layer of 0.5% low-melting-
point agarose was added, and slides were then immersed
for 1 h at 4 °C in the dark in cold lysis solution com-
posed of 2.5 M NaCl, 100 mM EDTA, 300 mM NaOH,
10 mM Tris, and 34 mM N-lauroylsarcosine (pH 10),
with 10% DMSO and 1% Triton X-100 added just before
use. Slides were placed in a submarine-type electrophor-
esis tank containing 300 mM NaOH and 1 mM EDTA
(pH 13.5) for 15min. Electrophoresis was then carried
out at 0.8 V/cm for 15min. Slides were rinsed three
Fig. 1 a Cytotoxic effects of MGDG on four human pancreatic cancer cells, as determined by the MTT assay. b Effects of MGDG, radiation and
their combination on NHDFs, as evaluated by the MTT assay
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times with neutralization buffer (0.5 M Tris, pH 7.4) and
stained with a solution of 1 μl SYBR Green Gold in
30 ml Tris/EDTA buffer.
Evaluation of in vivo tumor growth-inhibitory effect
Male BALB/cAJcl-nu/nu mice (4 weeks old; n = 10 per
group) were used for the xenograft model. Experiments
were carried out in strict accordance with institutional
ethics guidelines. Each mouse received a subcutaneous
intratumoral injection of 2 × 107 MIAPaCa-2 cells resus-
pended in the Matrigel (BD Biosciences) and were then
randomly divided into the following four groups: con-
trol, MGDG (injection with 2 mg MGDG solution twice
on alternate days to ensure good penetration into the
tumors), irradiation (5 Gy), and the combination of both.
For this procedure, MGDG was used at a concentration
of 50 mg/ml (62.5 mM) in solvent, and 4 mg MGDG
solution (two injections of 2-mg MGDG solution) were
used to prepare 50 μM MGDG. To assess the tumor
growth-inhibitory effect of MGDG and/or radiation,
tumor size was measured two or three times a week by
calculating the volume using the formula L ×W2 × (π/6),
where L and W are the longest and shortest diameters
of the tumor, respectively. All animal experiments were
approved by the Institutional Animal Care and Use
Committee (permission no. 100605R1) and were per-
formed according to Kobe University Animal Experi-
mentation Regulations.
Statistical analysis
Data are presented as mean ± standard error. Differences
between groups were evaluated with the Student’s t
test. Data were considered statistically significant at
P < 0.05.
Fig. 2 Colony-forming assay of MIAPaCa-2, BxPC-3 and AsPC-1 cells after exposure to graded doses of X-ray radiation combined with
MGDG. *P < 0.05
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Results
Cell viability
Compared to DGDG or SQDG, MGDG showed distinct
cytotoxic effects on human cancer cell growth (Table 1).
MGDG showed dose- and time-dependent cytotoxicity
in all four human pancreatic cancer cell lines, as deter-
mined with the MTT assay (Fig. 1a). The half-maximal
inhibitory concentrations (IC50) in MIAPaCa-2, BxPC-3,
AsPC-1 and PANC-1 cells at 72 h were 18.5 ± 1.7, 26.9
± 1.3, 22.7 ± 1.9, and 25.6 ± 2.5 μM, respectively. In con-
trast, MGDG showed almost no cytotoxicity in NHDFs,
and combined MGDG treatment and irradiation did not
have a synergistic effect in NHDFs as compared to ir-
radiation alone (Fig. 1b). The colony forming assay re-
vealed fewer MIAPaCa-2, BxPC-3 and AsPC-1 cell
colonies upon treatment with the combination treatment
as compared to irradiation alone (P < 0.05) (Fig. 2).
Induction of apoptosis
The single treatments increased the rate of apoptosis
(5.2% for MGDG and 8.8% for radiation), while the com-
bination of both yielded a higher proportion of apoptotic
cells (21.5%), suggesting that they had a synergistic effect
on apoptosis induction (Fig. 3).
Molecular events underlying apoptosis in MIAPaCa-2
cells treated with MGDG were investigated by the west-
ern blotting. Cytochrome c release from mitochondria
to the cytosol increased in a concentration-dependent
manner in the presence of 50 and 75 μM of MGDG; that
is, cytochrome c level was reduced in mitochondria and
increased in the cytosol relative to control cells (Fig. 4a, b).
The activation of cleaved PARP and cleaved caspase-3 was
also increased by MGDG treatment (Fig. 4c, d), with the
latter possibly resulting from increased mitochondrial re-
lease of cytochrome c. Bax was also upregulated in a dose-
dependent manner at 25 an 50 μM, whereas Bcl-2 level
remained largely unaffected (P < 0.05) (Fig. 4e, f). A possible
reason for slight decrease in Bax and Bcl-2 levels at 75 μM
MGDG is cell loss caused by severe MGDG toxicity.
Results from the western blot analysis were compared with
the Student’s t test [22].
DNA damage and DNA repair impairment
The effects of MGDG and radiation on the cellular
DNA damage response was evaluated by quantifying γ-
H2AX foci in MIAPaCa-2 cells. Compared to irradiation
alone, combination treatment increased the number of
γ-H2AX foci in MIAPaCa-2 cells (Fig. 5a, b). The results
indicate that MGDG and irradiation induce DNA dam-
age in a synergistic manner.
We performed the alkaline comet assay to detect defects
in DNA repair. At 30min, the proportion of comet tails in-
dicating DNA fragments was higher in the combination
treatment (46.5%) than in the MGDG (3.2%) and irradi-
ation (30.5%) groups (P < 0.05) (Fig. 5c). At later time
points, most cells had completed DNA repair or had under-
gone apoptosis. These results indicate that MGDG potenti-
ated the suppressive effects of radiation on DNA repair.
Fig. 3 Induction of apoptosis after MGDG, irradiation and their combination in MIAPaCa-2 cells. a Control, b 25 μM MGDG, c 5 Gy radiation, d combination
of 25 μM MGDG and 5 Gy radiation
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Cell cycle distribution
To determine whether cell cycle was affected by MGDG
or irradiation, MIAPaCa-2 cell cycle distribution was
analyzed by flow cytometry. MGDG induced a slight in-
crease in the G2/M fraction (29.9–36.2%) (Fig. 6a, b),
while irradiation caused G2/M arrest (29.9–65.3%)
(Fig. 6a, c). The cell cycle distribution following com-
bination treatment was similar to that of irradiation
alone (Fig. 6c, d). These results indicate that MGDG
does not act synergistically with radiation to induce
cell cycle arrest.
Tumor growth inhibitory effect
The effects of MGDG and radiation were assessed in a
mouse xenograft model using MIAPaCa-2 cells. After
23 days, the tumor volumes were 7475.3 ± 986.1 mm3
(control), 7598.8 ± 1532.0 mm3 (MGDG), 5892.7 ±
1313.3 mm3 (radiation), and 2539.8 ± 552.7 mm3 (MGDG
and radiation) (Fig. 7a, b). The tumor growth inhibitory
effect was greater in mice receiving intratumoral injection
of MGDG combined with irradiation as compared to
either of these approaches alone (P < 0.05) (Fig. 7b).
Discussion
In our previous study, MGDG was found to selectively in-
hibit mammalian pols α, γ, δ and ε while having no effect
on other mammalian pols, such as those related to repair
(β, η, ι, κ, λ and μ) or terminal deoxynucleotidyl transfer-
ase activities [21]. In the present study, we found that
MGDG suppressed proliferation of various cancer cell
types, including pancreatic cancer cells. Given that the
50% lethal dose (LD50) for suppression of cell growth by
MGDG is nearly equivalent to the IC50 for inhibition of
polymerase activities, we speculate that MGDG penetrates
cancer cells and inhibits the activities of mammalian nu-
clear DNA repair pols δ and ε as well as the mitochondrial
DNA repair pol γ, leading to radiosensitization and cell
growth suppression. We also compared the growth-
inhibitory effects of MGDG with those of other spinach
glycoglycerolipids in several cancer cell lines (Table 1).
Fig. 4 Molecular events underlying apoptosis in MIAPaCa-2 cells treated with MGDG. a Cytochrome c in mitochondria, b Cytochrome c in the
cytosol, c PARP and cleaved PARP, c Pro caspase-3 and cleaved caspase-3, e Bax and f Bcl-2 levels were determined by western blotting. Protein
levels were evaluated relative to HSP-60 or actin. *P < 0.05
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Interestingly, the MGDG had more potent cytotoxic ef-
fects than these two compounds in all cell types examined,
consistent with a previous report [9].
Pancreatic cancer is a lethal disease; the 5-year survival
rate is approximately 3–7% following diagnosis [1, 2].
Surgical resection is the only curative treatment but the
majority of patients are diagnosed at late, inoperable
stages. Locally advanced pancreatic cancer (LAPC) is re-
sistant to many forms of chemoradiotherapy (CRT) [3].
CRT with concurrent 5-fluorouracil was previously con-
sidered as a standard treatment for LAPC [25, 26]. More
recently, based on favorable responses to GEM-based
chemotherapy [27, 28] and the observation that GEM is
a potent radiosensitizer [29], GEM-concurrent CRT has
been used to treat LAPC [30, 31], with improved
survival rates. Since conventionally fractionated chemo-
radiotherapy is associated with 1-year local control rates
of only 40–60%, a strategy to enhance the effects of radi-
ation is necessary. To this end, our observation of radio-
sensitization by MGDG suggests that it can be a possible
treatment option for LAPC. A recent study reported
successful results by combining GEM with proton ther-
apy to treat LAPC; the 1-year local progression-free and
overall survival rates were 81.7 and 76.8%, respectively
[32]. Alternatively, stereotactic body radiation therapy
can potentially achieve high local controllability in the
management of pancreatic cancer [33, 34]. However,
these methods have also been associated with a high in-
cidence of acute morbidity [32, 33]. Given that MGDG
enhances the effects of GEM in pancreatic cancer cell
Fig. 5 DNA damage and repair in MIAPaCa-2 cells after MGDG (25 μM for 24 h), radiation (8 Gy for 12 h), or both. a Detection of DNA damage
by γ-H2AX foci staining. b Quantification of γ-H2AX-positive cells. c Comet assay for detection of DNA fragments. *P < 0.05
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Fig. 6 Cell cycle distribution in MIAPaCa-2 cells after treatment with MGDG, radiation or both. a Control, b MGDG (25 μM for 24 h), c radiation
(8 Gy for 12 h), and d combination of 25 μM MGDG for 24 h and 8 Gy radiation for 12 h
Fig. 7 Tumor growth inhibitory effect of MGDG combined with irradiation. a Tumor appearance in xenografts 23 days after treatment
(arrowhead). b Sequential measurements of tumor size after each treatment. Data are shown as mean ± SE. * P < 0.05
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lines [21] as well as those of irradiation in this study, the
therapeutic efficacy of MGDG combined with a lower
dose of GEM or with radiotherapy should be tested as a
means of reducing the morbidity of chemoradiotherapy
for LAPC.
Most chemotherapeutic agents do not significantly im-
prove the survival of pancreatic cancer patients [35].
Dysregulation of pro-apoptosis signaling is a survival
mechanism for pancreatic cancers. Given that nearly
every step of carcinogenesis inhibits apoptosis, the devel-
opment of therapeutic strategies that target this process
is essential for effective treatment of pancreatic cancer
[36]. MGDG was recently introduced as a novel antican-
cer agent that can potentially increase apoptosis rates in
human cancer cell lines. We previously showed that
combining MGDG and GEM induced cell death and
apoptosis [21]. In this study, MGDG showed dose-
dependent cytotoxicity in pancreatic cancer cell lines, as
evidenced by increased mitochondrial cytochrome c re-
lease and activation of caspase-3 followed by PARP,
which resulted in apoptosis. Radiation causes DNA dam-
age and kills mammalian cells by inducing single- and
double-strand breaks in DNA [37]. The fact that the
combination treatment showed greater cytotoxicity in
vitro and in vivo than either approach alone indicates
that the inhibitory effects of radiation on DNA are syn-
ergistically enhanced by MGDG.
MGDG alone or combined with radiation had negli-
gible cytotoxicity in NHDFs as determined by the MTT
assay, which is consistent with previous findings [21].
We used this as opposed to the colony forming assay
since these cells did not form measurable colonies.
However, one limitation of this study is that the pos-
sible side effects of MGDG were not fully investigated;
specifically, the toxicity at high doses caused by its in-
hibition of DNA polymerase activity warrants further
investigation. The side effects of MGDG are presum-
ably similar to those caused by pyrimidine analogs such
as GEM and cytarabine. GEM is widely used to treat
various types of malignancy including non-small cell
lung and breast cancers and is a key drug for the treat-
ment of pancreatic cancer [38]. An in vivo model in
which various doses are tested followed by a phase I
clinical study can clarify the potential side effects of
MGDG. Another limitation is that administration of
MGDG was tested by intratumoral injection. In an earl-
ier study, tumor growth was slightly inhibited by the
oral administration of spinach glycolipid fractions con-
taining MGDG, DGDG and SQDG [8]; however, oral
administration of a single compound (e.g., MGDG)
combined with irradiation has not been previously
assessed. Using different modes of administration could
potentially clarify the efficacy of MGDG for the treat-
ment of pancreatic cancer.
Conclusions
This is the first report providing evidence that MGDG
enhances the cytotoxic effects of radiation in pancre-
atic cancer cells in vitro and in vivo. This effect is likely
associated with stimulation of mitochondrial cyto-
chrome c release. Combined treatment with MGDG
and radiation synergistically suppressed tumor growth
in vivo. Our findings indicate that this therapeutic
combination can be an effective strategy for the treat-
ment of pancreatic cancer.
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